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Context. Polycystic ovary syndrome (PCOS) is a chronic disease affecting reproductive 31 
function and whole-body metabolism. While the aetiology is unclear, emerging evidence 32 
indicates that the epigenetics may be a contributing factor.  33 
Objective. To determine the role of global and genome-wide epigenetic modifications in 34 
specific immune cells in PCOS compared to controls and if these could be related to clinical 35 
features of PCOS.  36 
Design. Cross-sectional study   37 
Participants. Women with (n=17) or without PCOS (n=17). 38 
Setting. Recruited from the general community.  39 
Main Outcome Measure(s). Isolated peripheral blood mononuclear cells were analysed using 40 
multi-colour flow cytometry methods to determine global DNA methylation levels in a cell 41 
specific fashion. Transcriptomic and genome-wide DNA methylation analysis was performed 42 
on T helper cells using RNA-sequencing and Reduced Representation Bisulfite Sequencing.  43 
Results. Women with PCOS had lower global DNA methylation in monocytes (p=0.006), T 44 
helper (p=0.004), T cytotoxic (p=0.004), and B cells (p=0.03). Specific genome-wide DNA 45 
methylation analysis of T helper cells from women with PCOS identified 5,581 differentially 46 
methylated CpG sites. Functional gene ontology enrichment analysis showed that genes located 47 
at the proximity of differentially methylated CpG sites belong to pathways related to 48 
reproductive function and immune cell function. However, these genes were not altered at the 49 
transcriptomic level. 50 
Conclusions. It was shown that PCOS is associated with global, and gene-specific DNA 51 
methylation remodelling in a cell-type specific manner. Further investigation is warranted to 52 
determine whether epigenetic reprogramming of immune cells is important in determining the 53 





Polycystic ovary syndrome (PCOS) is a metabolic and reproductive disorder with a complex 57 
and ill-defined aetiology. It is commonly characterised by increased levels of androgens, 58 
inflammatory cytokines, insulin resistance and increased prevalence of sub-fertility 1-3. 59 
Familial clustering of PCOS is well documented, providing evidence for a heritable component 60 
of the syndrome 4,5. However, investigations to identify the single nucleotide polymorphisms 61 
(SNPs) that may underpin the genetic basis of PCOS have been inconclusive despite recent 62 
advances in the field from genome-wide association studies (GWAS) 6-9.  63 
 64 
Emerging evidence suggests a role for altered epigenetic programming in the aetiology of 65 
PCOS 10-14. Genome-wide analysis of transcriptomic, and DNA methylation status have been 66 
conducted in adipose tissue and skeletal muscle revealing tissue-specific epigenetic, and 67 
transcriptomic differences between women with and without PCOS 13,14. In adipose tissue, 68 
DNA methylation analysis revealed aberrant patterns in pathways involved in adipogenesis, 69 
inflammation, glucose regulation and energy metabolism, and these DNA methylation sites 70 
corresponded with 30 differentially expressed genes 13. Similarly, in skeletal muscle, 71 
transcriptomic analysis found significantly enriched pathways in immune function, and disease 72 
14. Finally, both adipose tissue and skeletal muscle showed inflammation as a significantly 73 
enriched pathway. This is important because immune cells play a critical role in metabolism, 74 
reproductive function, are the main source of inflammatory cytokines and are known to be 75 
epigenetically regulated 15-19. These studies provide important insights into the potential 76 
contribution of epigenetic changes to the development of PCOS and rationale for further 77 
investigation into epigenetic changes in other cell types that may be affected in PCOS, such as 78 
immune cells. In both animal PCOS models, and women with PCOS, altered immune 79 
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responses, and inflammatory markers have been found in various ovarian tissues, suggesting a 80 
role in the pathophysiology of the reproductive features of PCOS 20-22. Impairment of immune 81 
cell function and the infiltration of these cells in insulin sensitive tissues has been shown to 82 
cause metabolic impairment and contribute to the onset of type 2 diabetes mellitus (T2DM) 83 
23,24. Thus, epigenetic remodelling of immune cells can be associated with impaired immune 84 
function and contribute to metabolic dysfunction in PCOS 15,25,26.  85 
 86 
Only one study has investigated the contribution of global epigenetic changes in immune cells 87 
from women with PCOS 27. In this study, they measured global DNA methylation (i.e. total, 88 
non-site-specific methyl-cytosine abundance) in a mixed population of immune cells known as 89 
peripheral blood mononuclear cells (PBMCs) from women with or without PCOS and failed 90 
to find any difference 27. There is increasing evidence supporting that epigenetic changes that 91 
occur within specific cell subtypes could be masked by analyses of whole blood 28. Therefore, 92 
cell-type specific global, and genome-wide methylation analysis may reveal a potential role of 93 
epigenetics in the immune system especially in PCOS28-30. In the present study we hypothesised 94 
that specific immune cell populations will present a different DNA methylation profile in 95 
women with PCOS compared to women without PCOS28,31. Using global and genome-wide 96 
DNA methylation analysis we aimed to explore epigenetic remodelling in specific immune 97 
cell-subtypes, most notably in T-Helper cells.  98 
 99 
Materials and methods 100 
Study population 101 
Premenopausal women (n=34) aged between 18-45 years with or without PCOS were recruited 102 
from the local community (i.e. a non-clinical population). All participants provided informed 103 
written consent. Women with PCOS were confirmed by an endocrinologist (SS or AJ) to have 104 
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features consistent with the Rotterdam diagnostic criteria based on participant’s previous 105 
medical records. The Rotterdam criteria was used for confirmation of PCOS with two of the 106 
following (i) oligo- or anovulation (ii) clinical (hirsutism and acne) and/or biochemical 107 
hyperandrogenism (iii) polycystic ovaries on ultrasound and exclusion of other causes of 108 
hyperandrogenism 32,33. Women without PCOS had no features of PCOS. Exclusion criteria 109 
were pregnancy, smoking, T2DM, known cardiovascular disease, asthma and medications 110 
affecting endpoint measures including: hormonal contraceptives, insulin sensitising drugs, 111 
anti-inflammatories and anti-androgens. This study was approved by the Victoria University 112 
Human Research Ethics Committee (HRE 14-138).  113 
 114 
Clinical measures 115 
All clinical measures were collected in the morning after an overnight fast. For women without 116 
PCOS, testing was conducted in the early follicular phase of the menstrual cycle (2-7 days after 117 
beginning menses). All women with PCOS had irregular cycles and therefore the testing was 118 
conducted in early follicular phase when possible.  119 
 120 
Lifestyle monitoring 121 
In the seven days preceding the trial, participants recorded their dietary intake via a 7-day food 122 
diary. Food diaries were analysed by FoodWorks® (Xyris) for the major food groups (grains, 123 
fruit, vegetables, protein and dairy), total energy (macronutrients) and fat ratios. Moderate-to-124 
vigorous physical activity was measured via an ActiGraph (GTX3+) accelerometer 125 
(Actigraph). Participants wore the monitor on their right hip during waking hours for seven 126 
days, except for bathing and swimming. Data was downloaded in 1-minute epochs and non-127 
wear time was defined as at least 20 minutes of zero counts. Daily moderate-to-vigorous 128 
physical activity was defined as all wear-time minutes and was calculated based on the 129 
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Freedson accelerometer age-cut points 34. Self-reporting physical activity was measured via the 130 
International Physical Activity Questionnaire (IPAQ). 131 
 132 
Anthropometric assessment  133 
Height and weight were measured to calculate body mass index (BMI): [body weight (kg)/ 134 
height squared (m2)]. Waist and hip circumference measurements were recorded 35. Fat mass, 135 
abdominal fat mass and fat free mass were measured by dual-energy x-ray absorptiometry 136 
(DXA): [GE Lunar iDXA] and analysed by a qualified DXA operator (DH).   137 
 138 
Fasting blood samples 139 
A sterile polyethylene catheter was inserted into the antecubital vein and baseline blood 140 
samples were collected. Plasma and serum were collected in the appropriate blood tubes via 141 
centrifugation and stored at -80ºC until analysis. Blood for PBMCs isolation was collected in 142 
three acid citrate dextrose tubes (BD) and left at room temperature until ficoll gradient 143 
separation on the same day as described below 28. 144 
 145 
Oral glucose tolerance test 146 
After collecting fasting baseline blood samples, participants then underwent an oral glucose 147 
tolerance test (OGTT) via ingestion of a 75g glucose drink over a 5 minute period with blood 148 
samples collected at 30, 60, 90 and 120 minutes 36. Blood glucose in plasma was measured on 149 
the day by using an automated analyser (YSI 2300 STAT Plus). Blood cell counts were 150 
measured on the day by haematology automated analyser (Sysmex). 151 
 152 
Biochemical analysis  153 
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The following assays were completed in house at Victoria University. Plasma insulin 154 
concentration was determined by radioimmunoassay according to manufacturer instructions 155 
with an intra and inter variability of 4.2% and 3.8% respectively (HI-14K, EMD, Merck 156 
Millipore). Results from the OGTT were used to determine both insulin sensitivity and 157 
resistance using area under the curve for plasma insulin and glucose concentrations and the 158 
homeostasis assessment (HOMA) indices of insulin sensitivity calculated as (fasting insulin x 159 
fasting glucose/22.5) 36. Interleukin-6 (IL-6) was measured using a high sensitivity ELISA with 160 
an intra assay variability of 7.6% (ab46042, Abcam). S-adenosylmethionine (SAM) was 161 
determined by competitive enzyme immunoassay and had an intra assay variability of 8.8% 162 
(STA-672, Cell Biolabs).  163 
 164 
The following assays were completed in the accredited pathology laboratory at Monash Health, 165 
Australia. Lipid profiles (Cholesterol, Triglycerides, LDL and HDL) were quantified by 166 
automated enzymatic methods (Architect C18000 analyser), high sensitivity C reactive protein 167 
(hs-CRP) by a highly sensitive Near Infrared Particle Immunoassay using the Beckman Coulter 168 
Synchron LX system Chemistry Analyser (Beckman Coulter). Folate was determined by the 169 
Access/DXI Folate assay which is a competitive binding receptor assay performed on the 170 
Beckman Coulter Unicel DXI 800 (Beckman Coulter). Homocysteine was measured using a 171 
Beckman Coulter Synchron DXC800 system Chemistry Analyser (Beckman Coulter). AMH 172 
was analysed using an enzyme‐linked immunosorbent assay (A16507, Immunotech, Beckman 173 
and Coulter Company). The sex hormone binding globulin (SHBG) assay was performed using 174 
a sequential two-step immunoenzymatic (‘sandwich’) assay carried out on a Beckman Coulter 175 
Unicel DXI 800 (Beckman Coulter). Testosterone was measured using high performance liquid 176 
chromatography–mass spectrometry (HPLCMS/MS) method using a liquid sample extraction 177 
(AB Sciex Triple Quad 5500 LC/MS/MS system). Free androgen index (FAI) was calculated 178 
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as (total testosterone x 100)/SHBG. Free testosterone (fT) was calculated by the Södergard free 179 
Testosterone calculation 37. 180 
 181 
PBMCs isolation  182 
PBMCs were isolated by ficoll gradient as previously described in 28 with some modifications. 183 
After centrifugation (1200 x g for 20 mins, brake off) and removal of plasma, the cell 184 
suspension was diluted in Roswell Park Memorial Institute medium (RPMI, Thermofisher), 185 
supplemented with penicillin/streptomycin and L-glutamine and carefully layered on ficoll in 186 
SepmateTM tubes (Stemcell technologies) in equal volumes and centrifuged. The buffy coat 187 
containing PBMCs was collected, washed with RPMI, and resuspended in autologous plasma. 188 
Cells were counted on the automated cell counter (TC20TM automated cell counter, Bio-Rad) 189 
before being frozen in 10% Cyropreservent DMSO in RPMI overnight in a controlled rate 190 
freezing container (CoolCell®, Biocision) and transferred to liquid nitrogen the following day 191 
for long-term storage. 192 
 193 
Global DNA methylation 194 
Global methylation in PBMCs was quantified as previously described 28. Briefly the cells were 195 
stained with an antibody cocktail of anti CD3-phycoerytrin conjugated, CD8- and CD14-196 
peridinin chlorophyll conjugated, CD4- and CD19-allophycocyanin conjugated (Becton-197 
Dickinson). Cells were then further stained with anti-5-methylcytosine (5meC, AbD serotec, 198 
Bio-Rad) or with its associated isotope control (Mouse, IgG1, BD) labelled with Alexa Flour 199 
488 according to manufacturer’s instructions (Zenon Alexa Flour 488 Mouse IgG1, Molecular 200 
probes, Life Technologies). Cells were incubated (20 min in the dark at room temperature) and 201 
then run immediately on the flow cytometer (FACS Calibur, BD). A specific gating strategy 202 
(supplemental figure 1) was used to separate the different cell populations and the median 203 
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fluorescence intensity (MFI) was measured and normalised by the MFI from the isotope 204 
controls for each cell population. Data were analysed using FlowJo version 10 (Tree Star) and 205 
Cytobank (Cytobank Inc). 206 
 207 
Cell sorting  208 
Cryopreserved PBMCs were thawed and immediately resuspended in RPMI before being 209 
washed and stained with anti-CD3 (APC), anti-CD4 (PE), anti-CD8 (Brilliant Violet or BV 210 
510), anti-CD19 (BV421), anti-CD20 (PE-Cyanine or Cy7) and anti-CD14 (APC). All 211 
antibodies were sourced from BD Biosciences (supplementary table 138). The stained PBMCs 212 
were washed twice in sort buffer [PBS 1% BSA, 25mM HEPES (pH=7.0), 1mM EDTA] before 213 
being sorted into four populations (monocytes, T helper, T cytotoxic, and B Cells) using the 214 
FACS-Aria (BD). 215 
 216 
RNA sequencing 217 
Total RNA from T helper cells was extracted using the Qiagen all prep DNA/RNA/miRNA 218 
universal kit (#80224, Qiagen) following manufacturer’s instructions. Quality of RNA was 219 
established using the Agilent RNA 600 Nano kit and Bioanalyser instrument (Agilent 220 
Technologies). RNA sequencing was performed according to Illumina TruSeq Stranded Total 221 
RNA with Ribo-Zero Gold protocol (Illumina) as previously described 39. Each library was 222 
quantified to ensure optimum cluster densities across every lane of the flow cell using the Qubit 223 
dsDNA HS assay kit (Invitrogen). Quality control for base pair size and purity was assessed 224 
using the Agilent High Sensitivity DNA chip and Bioanalyser instrument (Agilent 225 
Technologies). Each library was diluted to 1nM before being pooled and measured on the 226 




Reduced representation bisulphite sequencing (RRBS) 229 
Genomic DNA was extracted from T helper cells using the Qiagen all prep DNA/RNA/miRNA 230 
universal kit (#80224, Qiagen) following manufacturer’s instructions. RRBS was performed 231 
using Diagenode Premium RRBS Kit (#C02030033, Diagenode) following manufacturer’s 232 
instructions. Each library was quantified using the Qubit dsDNA HS assay kit (Invitrogen) and 233 
quality controlled for base pair size and purity using the Agilent High Sensitivity DNA chip 234 
and Bioanalyser instrument (Agilent Technologies). Genome-wide DNA methylation of T 235 
helper cells was measured on the Illumina Next Seq 500 (Illumina). 236 
 237 
Transcriptomic analysis 238 
RNA-seq raw reads were aligned to human genome (hg38) using STAR 40 and gene coverages 239 
were computed by featureCounts 41 using Gencode annotation 42. The ribosomal RNA counts 240 
were excluded from the downstream analysis. Libraries with less than 15 million assigned reads 241 
were removed from analysis. A generalised linear model (y ~ 0 + disease) was fitted for disease 242 
factor by using DEseq2 pipeline 43. Genes with a false discovery rate (FDR) below 0.1 were 243 
considered differentially expressed. 244 
 245 
Approximately 15 million reads/sample were assigned to genes with 38 genes surviving the 246 
expression threshold (q<0.1). Molecular functions and biological processes were established 247 
from the Universal Protein Resource (UniProt) which is a comprehensive resource for protein 248 
sequence and annotation data. The Kyoto Encyclopaedia of Genes and Genomes (KEGG) 249 
database investigated the interaction of molecular pathways that were associated with the 250 
identified differentially expressed genes. This provided an in-silico indication of the molecular 251 




RRBS analysis 254 
RRBS reads were processed with the ‘rrbs’ setting of Trim Galore v0.3.7 and Cutadapt v1.4.2. 255 
Processed reads were mapped to hg38 followed by derivation of CpG methylation using 256 
Bismark 44. Mappings to Y chromosome was removed for the differential methylation analysis. 257 
Differential methylation analysis was conducted on site and region level according to the 258 
sample groups (PCOS v CON) by using RnBeads pipeline 45. For each library, SNP-enriched 259 
sites were removed and sites with less than 10 counts were masked. Gene ontology (GO) 260 
enrichment analysis was conducted to determine significant GO terms using a hypergeometric 261 
test and a rank cut-off applied for the top 100 best ranking regions in RnBeads pipeline. 262 
 263 
Statistical analysis 264 
Data were analysed using IBM SPSS Statistics, version 22 (Armonk, NY). Baseline 265 
characteristics are presented as mean ± SD or median (IQR), when data were skewed. The 266 
baseline characteristics between PCOS and control groups were compared using student t-tests 267 
if data was normally distributed. Data were tested for normality using the Shapiro-Wilk test 268 
and when deemed non-normal the Mann Whitney test was used to compare the baseline 269 
characteristics. Student t-test were used to examine the difference in global DNA methylation 270 
between women with and without PCOS. Statistical significance was accepted when p<0.05. 271 
To get insight into the relationship between clinical perturbations and DNA methylation in 272 
blood, we performed spearman correlation analyses in women with or without PCOS for each 273 
population of PBMCs, assessing the association between body composition, physical activity, 274 
dietary intake and hormones with global DNA methylation. After adjusting for multiple 275 
comparisons statistical significance was accepted when false discovery rate (FDR) q0.1. The 276 
datasets generated and/or analysed during the current study are available in the NCBI’s Gene 277 





Clinical and biochemical characteristics 281 
All 17 women with PCOS had irregular cycles or amenorrhea; 14 had clinical or biochemical 282 
hyperandrogenism, and 15 had polycystic ovaries on ultrasound. Women without PCOS did 283 
not display any of the three clinical features detailed by the Rotterdam criteria 33,47. Detailed 284 
clinical characteristics of the 34 women (n=17 PCOS; n=17 without PCOS) who participated 285 
in study are reported in Table 1. There were no differences in age, height, weight, body mass 286 
index (BMI), markers of body composition, physical activity, energy, and macronutrient intake 287 
between women with or without PCOS (Table 1). There were also no differences in the lipid 288 
profile, circulating methyl donors (SAM or homocysteine), cytokines (interleukin or IL-6 and 289 
high sensitivity C - reactive protein), or a difference in the fasting and the postprandial response 290 
to the oral glucose tolerance test (OGTT) and homeostatic model assessment for assessing 291 
insulin resistance (HOMA-IR) (Table 2). There was a tendency for folate to be higher in women 292 
with PCOS (p=0.08). Women with PCOS showed a higher area under the glucose curve 293 
(p=0.02) during the OGTT compared with women without PCOS, but there was no difference 294 
observed for area under the insulin curve between groups (Table 2). Women with PCOS had 295 
higher levels of free testosterone (fT) (p<0.01), free androgen index (FAI) (p<0.01) and anti-296 
müllerian hormone (AMH) (p<0.01) (Table 2).  297 
 298 
Global DNA methylation  299 
Global DNA methylation analysis of the individual immune cell populations was performed 300 
using an antibody that detects methylated cytosine bases coupled with FACS detection 28. We 301 
identified hypomethylation in monocytes (p=0.006), T helper (p=0.004), T cytotoxic 302 
(p=0.004), and B Cells (p=0.03) in women with PCOS compared to women without PCOS 303 
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(Figure 1). Furthermore, systemic AMH concentration was associated with global DNA hypo-304 
methylation in T helper (rs= -0.428, q=0.078), but not in T cytotoxic cells, B cells or monocytes 305 
(Table 3). Subset analysis revealed that the AMH associated hypomethylation in T helper cells 306 
was only observed in women with PCOS (p=0.035). fT was also associated with DNA 307 
hypomethylation in T helper (rs= -0.381, q<0.087), but not T cytotoxic cells, B cells or 308 
monocytes (Table 3). Collectively, our results show a cell-type specific alteration of global 309 
DNA methylation in immune cells in PCOS and suggest a correlation with the dysregulated 310 
ovarian hormone and hyperandrogenism as indicted by associations with AMH and fT 311 
respectively. 312 
 313 
DNA methylome of T helper cells 314 
To further explore the changes in the methylome of immune cells from women with PCOS, we 315 
investigated genome wide methylation levels in sorted T helper cells. We identified 5,581 CpG 316 
sites differentially methylated in women with PCOS in T helper cells. Of these sites, only 13 317 
were located within promoter regions or gene bodies (8 promoters and 5 gene bodies, Table 4). 318 
Gene enrichment analysis of the genes harbouring differentially methylated cytosine’s 319 
identified gene ontology (GO) terms related to T cell function, and reproductive function 320 
including; female pregnancy, response to prolactin, regulation of ovarian follicle development, 321 
progesterone receptor signalling pathway, male sex determination and response to steroid 322 
hormone (Supplementary Table 2-538). Thus, our results indicate that genes regulating 323 
reproductive function are epigenetically remodelled at in specific immune cells.  324 
 325 
Transcriptomic analysis of T helper cells 326 
To determine if the specific DNA methylation signature we identified in T helper cells is linked 327 
to transcriptional changes, we investigated gene expression via RNA sequencing. We found 37 328 
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genes differentially expressed between women with PCOS (Figure 2), compared to those 329 
without PCOS with 33 down-regulated and 4 were upregulated (Table 5). Surprisingly, none 330 
of the differentially expressed genes showed changes in DNA methylation as identified by 331 
reduced representation bisulphite sequencing (RRBS) analysis. Interestingly a large portion of 332 
the differentially expressed transcripts (n=17) were long non-coding RNAs (lncRNA) 333 
including pseudogenes, long intergenic non-coding RNA (lincRNA) and Y RNA. The 334 
remaining 20 transcripts were protein-coding and related to inflammatory and immune cell 335 
function. KEGG analysis revealed that the cyclic guanosine monophosphate (cGMP) signalling 336 
and Bone morphogenetic pathway (BMP) signalling pathways were functionally enriched. 337 
BMP signalling was upregulated, whereas cGMP signalling was downregulated in women with 338 
PCOS. Taken together, our results indicate that epigenetic remodelling of genes related to 339 
reproductive function in T helper cells does not seem to be functional at the transcriptomic 340 
level in women with PCOS.  341 
 342 
Discussion 343 
Here, we report that immune cells from women with PCOS have a distinct epigenetic profile, 344 
at both global and gene-specific level. On the global level we found hypomethylation in all 345 
PBMCs sub-types. In the specific T-lymphocyte population, the differentially methylated 346 
genes that we identified were enriched for gene ontology terms related to T cell function, but 347 
also reproductive function, suggesting a role of epigenetic reprogramming in the reproductive 348 
defects associated with PCOS.  349 
 350 
Global DNA Methylation  351 
At the cell-type specific level, PBMCs from women with PCOS display distinct global DNA 352 
methylation levels compared to women without PCOS. Only one previous study reported that 353 
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global DNA methylation levels were not different in the total PBMCs fraction from women 354 
with PCOS 27. While we have not measured the global methylation of the total PBMCs fraction 355 
in the present study, differences at the cell-type specific level may not be detected when 356 
investigating global DNA methylation at the whole PBMC level. This would be consistent with 357 
a previous study showing no difference in global DNA methylation in total blood fractions 358 
from subjects with type 2 diabetes while global DNA methylation was altered in specific 359 
immune cell populations 28. Further consolidating the importance of measuring global DNA 360 
methylation in immune cells in a cell-type specific manner.  361 
 362 
Methylation of DNA is under the control of the one-carbon metabolism notably the methyl 363 
donor SAM, which is a cofactor necessary for the transfer of a methyl group to a cytosine base 364 
in DNA 48. To gain insight into the potential relationship between altered global DNA 365 
methylation levels in immune cells in PCOS and folate metabolism, we measured key one-366 
carbon metabolites: SAM, homocysteine and folate but found no differences. The lack of 367 
association between circulating one-carbon metabolites and global DNA methylation levels in 368 
immune cells from women with PCOS suggests that methyl donors may not be the primary 369 
driver of the global DNA hypomethylation observed in PCOS. Alternatively it would be 370 
interesting to investigate whether the enzymes DNA methyltransferases (DNMTs) or ten-371 
eleven translocation (TET), that are responsible for the transfer of the methyl group to the 372 
cytosine base or removal of methyl group respectively, may play a role in the hypomethylation 373 
observed in the immune cell populations 49. 374 
 375 
Lifestyle factors such as physical activity and diet have been previously associated with both 376 
global, and gene-specific DNA methylation changes 50-52. Obesity, as measured by BMI, is also 377 
associated with distinct DNA methylation patterns 28,31,53,54. In the present study, we did not 378 
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find any associations between global methylation and BMI, habitual physical activity or diet 379 
(total energy) in any of the cell subsets. These data do not support a role of adiposity, physical 380 
activity or caloric intake on the altered global DNA methylation in PBMCs from women with 381 
PCOS. Interestingly, we found a negative association between global methylation in T helper 382 
cells and circulating levels of AMH. This relationship is only present in women with PCOS 383 
who have elevated circulating levels of AMH, suggesting a mechanistic association of this 384 
hormone in PCOS and DNA methylation changes in T helper cells. AMH is a member of the 385 
transforming growth factor beta (TGF-β) ligand superfamily that is predominantly present in 386 
ovaries in healthy women but released into the circulation at elevated levels in PCOS 2,55-60 387 
although there is little literature indicating whether it is a cause or consequence. AMH has been 388 
found to cluster with many clinical markers of PCOS including positive correlations with LH, 389 
and androgens and negatively with FSH, and glucose levels 59,60. Furthermore, in women with 390 
PCOS, it has been shown that AMH disrupts folliculogenesis by decreasing sensitivity to FSH 391 
and thereby inhibiting follicle recruitment, and growth which can result in increased number 392 
of pre-antral and antral follicles and the PCO morphology 61,62. It has also been suggested that 393 
circulating AMH may have a functional role outside of the reproductive system 63. 394 
Interestingly, in immune cells, members of the TGF-β ligand superfamily are potent regulators 395 
of T cell activation and differentiation and control a variety of regulatory epigenetic signals 396 
such as chromatin remodelling, histone modification and DNA methylation 64-66. Based on our 397 
observations and considering the literature, we hypothesise that AMH participates in the 398 
epigenetic reprogramming of some subpopulations of PBMCs in women with PCOS 399 
warranting further research. 400 
 401 
Here we identified a negative correlation between global methylation in T helper cells and fT. 402 
In women with PCOS, fT is elevated and is used to diagnose hyperandrogenism in the 403 
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syndrome32. Elevated androgens in animal models are associated with reproductive 404 
dysfunction (oligo-anovulation, menstrual disturbances and sub-fertility) that is observed in 405 
PCOS 61,67-70. Androgens have immunomodulatory effects, and elevated androgens are 406 
associated with altered immune function that likely impacts reproductive function 71,72. 407 
Medawar73 identified the importance of the immune system in reproduction with further studies 408 
identifying the importance in the frequencies of T helper 1 (Th1), T helper 2 (Th2), T helper 409 
17 (Th17), and regulatory T (Treg) cells in maintenance of normal ovarian function, and 410 
menstrual cycles 73-76. Interestingly Th1/Th2/Th17 imbalances have been identified in women 411 
with PCOS 76-78. The differentiation of T cells and the ratios of Th1/Th2/Th17/Treg cells appear 412 
to be modulated by androgens 72,79-81. Furthermore, the differentiation of T cells are also 413 
modulated by epigenetic mechanisms 15,82,83 and this may be the case in PCOS 72. Altogether 414 
our data complements previous studies indicating the elevated fT was associated with 415 
differences in the methylome profile in T helper cells in women with PCOS. Whether 416 
hyperandrogenism modulates the epigenome of T helper cells and result in changes to 417 
frequency of Th1/Th2/Th17/Treg cells and the reproductive dysfunction in PCOS would be an 418 
interesting avenue to explore.  419 
 420 
DNA methylome, and transcriptomic analysis of T helper cells 421 
We also investigated genome-wide DNA methylation in T helper cells at the single nucleotide 422 
resolution and identified differentially methylated cytosine bases at the proximity of genes 423 
controlling reproductive function. Specifically, our gene ontology analysis returned terms such 424 
as female pregnancy, regulation of ovarian follicle development, and male sex determination.  425 
As the altered DNA methylation was present at genes controlling reproductive function in 426 
immune cells, this suggests that epigenetic changes may not be tissue specific. Instead, these 427 
methylation patterns may occur in multiple tissue-types that are exposed to specific extra-428 
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cellular stimuli (possibly elevated AMH levels or elevated androgens), with such exposure 429 
potentially occurring in-utero or as a result of the development of PCOS over the lifespan 84-430 
86. With epigenetic reprogramming of genes being related to reproductive function it would be 431 
worthwhile investigating other tissues, such as the ovary or neuro-endocrine tissues, where the 432 
appropriate transcriptional activators and co-activators are expressed 87,88. This would provide 433 
insights into the role of epigenetic reprogramming at genes controlling reproductive function 434 
on ovarian function and sex hormone imbalances in women with PCOS.  435 
 436 
We found no overlap between the transcriptomic, and DNA methylation data. This suggests 437 
that the shift in epigenetic signature could be related to differences in the proportions of T-438 
helper subpopulations (T helper 1, T helper 2, T helper 9, T helper 17, follicular T helper, 439 
regulatory, naïve, effector, and memory T cells) 89-91. Previous literature has shown in women 440 
with PCOS an increased frequency of the pro-inflammatory Th1 population and a reduced 441 
frequency of the in the anti-inflammatory Th2 population 76,78,79. While we were unable to 442 
confirm the frequency of T helper subpopulations, the gene ontology pathway analysis 443 
identified differential methylation in the activation and proliferation of different T helper 444 
subpopulations suggesting that women with PCOS may indeed have different proportions of 445 
the T helper sub-types (supplementary tables 2-538).  446 
 447 
To further consolidate this hypothesis, the transcriptomic analysis of the differentially 448 
expressed genes in T helper cells identified pathways that relate to T cell activation and 449 
differentiation. Of interest, KEGG analysis revealed that the Bone Morphogenic Protein (BMP) 450 
signalling pathway was upregulated in women with PCOS, and BMP, like AMH, is a member 451 
of the TGF-β ligand superfamily 92. The elevated circulating AMH found in our women with 452 
PCOS may explain the upregulation of BMP signalling in T helper cells via activation of the 453 
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BMP receptors (BMPR). AMH intracellular signalling works via the BMPR through Smad 454 
1/5/8 pathway, that assemble into a complex with Smad 4 (Co-Smad) and translocate into the 455 
nucleus activating a range of genes dependent on the cellular context 93-95. In T cells, the BMP 456 
signalling generally regulates activation and differentiation of circulating naïve immune cells, 457 
the proliferation of T helper 9, 17, and memory T cells 95,96. Despite the lack of quantification 458 
of T Helper cells frequency in women with and without PCOS, our data provides a potential 459 
mechanism by which the upregulated BMP signalling pathway could impact the Th1/Th2 460 
balance but warrant further studies 93,97. 461 
 462 
Several differentially expressed genes were associated with inflammation/inflammatory status 463 
(Table 5) in women with PCOS compared to those without. This supports the role of 464 
inflammation/inflammatory status consistent with previous studies 98, where ovulation requires 465 
an appropriate inflammatory reaction 18. In addition, circulating immune cells and the cytokines 466 
they produce are also involved in ovarian function 16,99,100. Suggesting that the epigenetic marks 467 
in our study can alter the transcriptome towards a pro-inflammatory T helper phenotype and 468 
suppress ovarian function.  469 
 470 
Many of the differentially expressed genes identified from our transcriptomic analysis were 471 
non-coding, with the majority being long non-coding RNAs (lncRNAs) including; 472 
pseudogenes, anti-sense RNA and long intergenic non-coding RNAs (lincRNA). LncRNAs are 473 
widely expressed and regulate gene expression particularly during development, differentiation 474 
and activation of immune cells 101 and have been implicated in the co-morbidities associated 475 
with PCOS including T2DM 102,103 and inflammatory disorders 104. There is also evidence to 476 
suggest that lncRNAs can act as a molecular scaffold for epigenetic modifications including 477 
DNA methylation and histone modifications 105,106. Indeed, the lack of overlap in our analysis 478 
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between DNA methylation and gene expression suggests that other mechanisms such as 479 
lncRNA modulating the transcriptomic in PCOS.  480 
 481 
The strength of this study is that this cohort was a well characterised, community recruited 482 
group of women with and without PCOS, who were otherwise healthy. We were adequately 483 
powered to answer our apriori aims with post hoc analysis revealing that we were powered on 484 
average 93% for all immune cells populations and had large effect sizes of approximately 0.90 485 
107. We acknowledge that there is a need for more definitive research into the molecular 486 
mechanisms behind each of the different the phenotypes of PCOS. While in the present study 487 
we were unable to confidently address the potential epigenetic differences between phenotypes 488 
in PCOS, we were able to explore the heterogeneous immune cell population and the unique 489 
role these may play in PCOS. These findings provide novel avenues for future research in 490 
PCOS including studying the role of methylation in specific immune cells in determining the 491 
different phenotypes in PCOS. 492 
 493 
In conclusion, our study in a small, yet well-characterised cohort of women with and without 494 
PCOS demonstrates novel epigenomic insights into PCOS. The specific epigenetic 495 
reprogramming of genes involved in reproductive function in immune cells from women with 496 
PCOS is intriguing and may indicate a role for epigenetic factors in the reproductive 497 
dysfunction and sex hormone imbalance associated with PCOS. Finally, we found that global 498 
DNA methylation in T helper cells is negatively associated with circulating levels of AMH and 499 
fT, suggesting the importance of the cellular milieu (elevated circulating androgens and AMH) 500 
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Table 1: Anthropometric data and lifestyle characteristics. 805 
Table 2: Metabolic and reproductive profile of participating women with and without 806 
PCOS. 807 
Table 3: Spearman correlations of apriori co-variates with global DNA methylation in T 808 
helper cells, T cytotoxic cells, monocytes, B cells across all participants. 809 
Table 4: Genes and promoters carrying differentially methylated CpGs in T helper cells 810 
from women with PCOS compared to women without PCOS.   811 
Table 5: Differentially expressed genes in T helper cells from women with PCOS 812 
compared to women without PCOS.  813 
 814 
Figures 815 
Figure 1: Lower 5-methylcytosine levels in monocytes, T helper, T cytotoxic and B cells 816 
in women with PCOS. Comparison of 5-methylcytosine median fluorescence intensity (MFI) 817 
between women with PCOS (square) and women without PCOS (circle). MFI normalised by 818 
the MFI from the isotope control. Significantly different from control *p<0.05 **p<0.01 819 
 820 
Figure 2: Volcano plots representing differentially expressed genes in T helper cells of 821 
women with PCOS compared to women without PCOS. Red circles highlight differentially 822 















Mean ± SD 
Median [IQR] 
With PCOS 




Age (years) 34 30.1 ± 6.6 28.9 ± 4.8 p=0.6 
Height (cm) 34 165 ± 7.2 162 ± 4.7 p=0.3 
Weight (kg) 34 70.5 ± 16.8 71.5 ± 18.2 p=0.9 
BMI (kg/m2) 34 25.5 ± 5.4 26.6 ± 6.9 p=0.6 
WHR 32 0.85 [0.8, 1.0] 0.80 [0.8, 0.9] p=0.2 
Body fat (%) 31 32.3 [25.9, 40.5] 37.7 [31.8, 41.8] p=0.3 
Physical activity 
PA (IPAQ-mins.week) 31 172 [15.0, 427.5] 165 [40.0, 255.0] p=0.6 
PA (Accel-mins.day) 30 47.0 [45.5, 48.5] 47.0 [46.0, 50.5] p=0.6 
Food intake 
Energy (g) 31 8269 [7033, 11402] 7744 [5509, 8885] p=0.2 
Saturated fats (g) 31 28.0 [23.0, 50.0] 21.5 [17.2, 30.3] p=0.07 
Carbohydrates (g) 31 198 [157, 278] 171 [144, 220] p=0.2 
Sugar (g) 31 70.0 [56.5, 118] 67.5 [51.0, 123] p=0.6 
BMI, body mass index; WHR, waist-to-hip ratio; IPAQ, International Physical Activity 831 
Questionnaire; MVPA; Moderate Vigorous Physical Activity; PA; physical activity.  832 
 833 














Cholesterol (mmol/L) 30 4.2 ± 0.7 4.4 ± 0.7 p=0.5 
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Triglycerides (mmol/L) 30 0.6 [0.6, 0.9] 0.8 [0.5, 1.0] p=0.6 
HDL(mmol/L) 30 1.5 ± 0.3 1.5 ± 0.3 p=1.0 
LDL (mmol/L) 30 2.5 ± 0.6 2.4 ± 0.7 p=0.6 
OGTT 
Fasting glucose (mmol/L) 34 4.9 [4.8, 5.4] 4.9 [4.6, 5.3] p=0.4 
Fasting insulin (pmol/L) 34 72.8 [56.2, 89.4] 68.5 [47.2, 102.4] p=0.9 
2hr glucose (mmol/L) 34 4.75 [4.5, 5.4] 5.5 [4.6, 5.8] p=0.2 
2hr insulin (pmol/L) 34 278 [207, 399] 309 [165, 737] p=0.5 
AUC Glucose (mmol/L) 33 665.8 ± 75.4 783.7 ± 167.8 p=0.02 
AUC Insulin (mmol/L) 33 48012 ± 18367 66180 ± 40350 p=0.11 
HOMA 34 2.65 [2.0, 3.2] 2.41 [1.7, 4.4] p=0.9 
Reproductive markers 
fT (pM) 34 23.2 [17.7, 31.2] 10.80 [10.3, 14.1] p<0.001 
SHBG (nmol/L) 34 62.1±21.5 63.4±38.4 p=0.9 
FAI 34 1.42 [1.4, 2.2] 3.17 [2.2, 5.3] p<0.001 
AMH (pmol/L) 33 18.9 [10.8, 31.1] 48.6 [37.7, 74.6] p<0.001 
Systemic methyl substrate/donors 
SAM (µg/mL) 32 7.7 [5.4, 8.3] 6.9 [6.0, 12.8] p=0.7 
Folate (nmol/L) 33 29.9 [23.2, 37.5] 37.3 [23.4, 45.8] p=0.08 
Homocysteine 33 9.0 [6.9, 10.1] 7.1 [6.4, 9.7] p=0.3 
Cytokines 
HsCRP (mg/L) 30 1.3 [0.5, 3.3] 1.4 [0.6, 4.5] p=0.7 
IL-6 (pg/ml) 31 1.8 [1.3, 3.0] 2.1 [1.5, 2.9] p=0.3 
Cell counts 
WBC (µL) 31 5335 ± 1229 5750 ± 1497 p=0.4 
OGTT, oral glucose tolerance test; AUC, area under the curve; HOMA, homeostatic model 836 
assessment, fT, free testosterone; SHBG, Sex Hormone Binding Globulin; FAI, Free Androgen 837 
Index; AMH, Anti-Müllerian Hormone; IL-6, Interleukin-6; HsCRP, High sensitivity C-838 
reactive protein; SAM, S-adenosylmethionine. 839 
31 
 
Table 3: Spearman correlations of apriori co-variates with global DNA methylation in T 840 
helper cells, T cytotoxic cells, monocytes, B cells across all participants. 841 
Covariate 
Spearman Correlation 
T helper T cytotoxic Monocytes B Cells 
BMI (kg/m2) 
rs 0.007 0.021 0.140 0.143 
p-Value 0.967 0.905 0.430 0.420 
FDR q-value 0.967 0.900 0.516 0.504 
PA  (MVPA 
mins.day) 
rs -0.139 -0.166 -0.165 -0.213 
p-Value 0.463 0.380 0.383 0.259 
FDR q-value 0.694 0.735 0.5164 0.504 
Energy (g) 
rs 0.070 -0.068 -0.069 -0.095 
p-Value 0.708 0.716 0.712 0.612 
FDR q-value 0.846 0.852 0.8546 0.612 
AMH (pmol/L) 
rs -0.428 -0.317 -0.286 -0.191 
p-value 0.013 0.072 0.106 0.288 
FDR q-value 0.078 0.432 0.351 0.504 
fT (pM) 
rs -0.381 -0.237 -0.278 -0.175 
p-Value 0.029 0.183 0.117 0.330 
FDR q-value 0.087 0.549 0.351 0.504 
AUC glucose 
(mmol/L) 
rs -0.160 -0.124 -0.152 -0.154 
p-Value 0.373 0.493 0.399 0.393 
FDR q-value 0.694 0.735 0.516 0.504 
BMI, Body Mass Index; MVPA, Moderate Vigorous Physical Activity; PA; physical activity; 842 
AMH, Anti-Müllerian Hormone; AUC, area under the curve. rs, Spearman’s Rho; fT, free 843 
testosterone. Significance was considered when false discovery rate (FDR) q<0.1.  844 
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Table 4: Genes and promoters carrying differentially methylated CpGs in T helper cells from women with PCOS compared to women 845 




Gene Name ENSEMBL 
Gene ID 
Chromosome Function and gene type 





SCGB1D4 secretoglobin family 1D member 4 ENSG000001
97745 
chr11 Regulation of chemotactic cell migration and invasion. 
NA AC025678.3  ENSG000002
79092 
chr15 TEC (To be experimentally confirmed) protein tyrosine kinase- 
involved in T cell signalling and activation 
NA AP006565.1 ENSG000002
79092 
chr18 anti-sense RNA 
NA AC104301.2 N/A chr20 ncRNA 
Promoter of genes 
Gene 
symbol 
Gene Name  Chromosome Function and gene type 
WBP11P1 WW domain binding protein 11 pseudogene 1 ENSG000002
60389 
chr2 pseudogene 
SCGB3A2 secretoglobin family 3A member 2 ENSG000001
64265 
chr5 receptor-mediated endocytosis 
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SCGB1D4 secretoglobin family 1D member 4 ENSG000001
97745 
chr11 regulation of chemotactic cell migration and invasion. 
OVCH1 ovochymase 1 ENSG000001
87950 
chr12 serine-type endopeptidase activity, hydrolase activity, 
 metal ion binding, proteolysis 
NA AP006565.1 ENSG000002
65737 
chr18 anti-sense RNA 
NA AC104301.2 N/A chr20 ncRNA 




Table 5: Differentially expressed genes in T helper cells from women with PCOS compared to women without PCOS.  848 
Down regulated genes in women with PCOS 
Gene name Gene symbol ENSEMBL Gene ID 
log2Fold 
Change 
padj Gene type Molecular function Molecular process 
NA AC138969.2 ENSG00000277920 -7.7 0.025 Pseudogene Unknown Unknown 
ring finger protein 
217 
RNF217 ENSG00000146373 -7.7 0.009 Protein coding 













guanylate cyclase 1 






























(class II), pi 
polypeptide 




trans retinal binding, 







solute carrier family 5 
member 11 
SLC5A11 ENSG00000158865 -6.6 0.025 Protein coding transporter activity 
transmembrane 
transport 
VWA8 antisense RNA 
1 (head to head)) 
VWA8-AS1 ENSG00000278338 -6.5 0.025 lncRNA Unknown Unknown 
NA Z98752.2 ENSG00000234271 -6.5 0.071 Processed pseudogene Unknown Unknown 
NA AC034102.3 ENSG00000257449 -6.5 0.044 lncRNA Unknown Unknown 
NA AC253536.6 ENSG00000272787.1 -6.4 0.009 LincRNA Unknown Unknown 
atypical chemokine 
receptor 2 






















NA RF00019 ENSG00000252652.1 -6.3 0.009 Y RNA Unknown Unknown 
protocadherin 
gamma subfamily B, 
8 pseudogene 




NA LOC101928238 ENSG00000278611 -6.3 0.074 LincRNA Unknown Unknown 
transmembrane and 
coiled-coil domains 2 
TMCO2 ENSG00000188800 -6.2 0.058 Protein coding Unknown Unknown 
CELF2 antisense 
RNA 2 
CELF2-AS2 ENSG00000237986 -6.2 0.052 lncRNA Unknown Unknown 
NA AC013476.1 ENSG00000234193.1 -6.1 0.025 lncRNA Unknown Unknown 
pannexin 3 PANX3 ENSG00000154143 -5.9 0.074 Protein coding 
wide pore channel 






NA RF00019 ENSG00000202222.1 -5.9 0.029 Y RNA Unknown Unknown 
NA LOC101927851 ENSG00000238005 -5.2 0.088 LincRNA Unknown Unknown 
leucine rich repeat 
containing 9 





EXTL3-AS1 ENSG00000246339 -5.1 0.040 lncRNA Unknown Unknown 
KIAA2012 KIAA2012 ENSG00000182329 -4.6 0.083 Protein coding Unknown Unknown 
NA AC013643.2 ENSG00000253875 -4.6 0.062 lncRNA Unknown Unknown 
cytochrome b 
reductase 1 







cellular iron ion 
homeostasis, response 
to iron ion, oxidation-
reduction process 
NA AC068620.2 ENSG00000270147 -4.1 0.078 LincRNA Unknown Unknown 
NA AC243428.1 ENSG00000229979 -4.1 0.037 Processed pseudogene Unknown Unknown 
stearoyl-CoA 
desaturase 
SCD ENSG00000099194 -2.7 0.058 Protein coding 
stearoyl-CoA 9-
desaturase activity, 











NIMA related kinase 
10 









positive regulation of 
protein 
autophosphorylation, 
positive regulation of 
MAP kinase activity, 
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regulation of ERK1 
and ERK2 cascade, 
regulation of cell cycle 






















negative regulation of 
transcription by RNA 
polymerase II, 
negative regulation of 
protein kinase 
activity, regulation of 
G2/M transition of 
mitotic cell cycle, 
negative regulation of 
protein import into 
nucleus, negative 
regulation of catalytic 
activity 
  849 
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mitochondrial fission, immune system process, defence response, response to virus, response to 
























chromatin silencing at rDNA, nucleosome assembly, telomere organization, interleukin-7-
mediated signalling pathway, negative regulation of gene expression, epigenetic, regulation of 













MAPK cascade, mesodermal cell fate commitment, osteoblast fate commitment, inflammatory 
response, transforming growth factor beta receptor signalling pathway, SMAD protein complex 




















Molecular functions and biological processes were established from the Universal Protein Resource (UniProt). False discovery rate (FDR) q<0.1.850 
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